DynPort Vaccine, a joint venture between Computer Sciences Corp. and Porton International, conducted a study involving 150 patients and a diluted dose of the company's smallpox vaccine, called CCSV. The vaccine, even when diluted up to 50 times, produced positive results in all but one of the 100 people who had not previously received a smallpox vaccination. CCSV is also associated with fewer side effects when compared to patients receiving the traditional smallpox vaccine, Dryvax.